-
2024-513858-29-01
4
2019-02-06
myelodysplastic syndrome with IDH2 mutated
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2023-504802-12-00
7
2018-05-16
Lymphoma of B-cell origin
-
2023-503469-49-00
5
2018-04-19
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
-
2023-506110-43-00
9
2018-01-25
Multiple Myeloma
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-513976-16-00
5
2015-06-26
squamous cell carcinomas of the larynx or hypopharynx locally advance
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2023-503803-27-00
5
2013-10-25
B-cell non-Hodgkin's lymphoma and cGVHD
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2024-513576-18-00
5
2020-07-17
Cervical Cancer
-
2024-515994-83-00
5
2026-01-13
aneurysmal subarachnoid hemorrhage with a vasospasm
-
2024-514946-35-00
4
2025-06-24
Sepsis-Induced Hypotension
-
2024-515933-14-00
1
2025-04-14
Pneumonia
-
2023-505499-32-00
5
2024-03-08
Uncontrolled hypertension (uTHN) defined as blood pressure that remain
-
2023-505985-28-01
4
2024-03-04
Severe Community-Acquired Pneumonia
-
2023-505108-52-00
5
2023-12-20
Intensive Care
-
2022-502584-38-00
5
2023-12-12
Locally advanced squamous cell carcinoma of the head and neck
-
2023-503270-20-00
3
2023-11-29
recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
-
2024-512554-15-00
5
2023-06-21
COVID-19
-
2024-512230-15-00
4
2023-05-20
Transient hyperglycaemia in premature infants